[Ip-health] European regulators say ‘yes’ to Shire’s Vpriv

Joana Ramos jdr at ramoslink.info
Tue Aug 31 07:00:55 PDT 2010


> http://www.pharmatimes.com/Article/10-08-31/European_regulators_say_yes_to_Shire_s_Vpriv.aspx
> Pharma Times
> 31 Aug. 2010
>
>
> The European Commission has granted marketing authorisation to Shire’s 
> Vpriv for the long-term treatment of type 1 Gaucher disease clearing 
> the drug’s use in 30 countries across the region..........
>

This is also  significant  because  Genzyme 's Cerezyme, the  until-now 
unique drug  for this type of Gaucher's and considered one of the 
world's most expensive medicines, has been in shortage status due to 
manufacturing problems:


29 June 2010
http://www.reuters.com/article/idCNN2915525820100629?rpc=44

17 March 2008
http://www.pharmalot.com/2008/03/at-300000-a-year-how-much-drug-is-too-much/


Shire has stated it will sell Vpriv at a price  15% loer than that of 
Cerezyme:
  http://www.reuters.com/article/idUSLDE67P1SV20100826


---------------
Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle WA USA
+1-206-229-2420
http://ramoslink.info/
www.bmtbasics.org
http://healthwatched.org




More information about the Ip-health mailing list